This seems like good news:
Makers of generic drugs hailed a proposal in President Barack Obama’s budget to set up a faster pathway for generic versions of biologic drugs, the fastest-growing segment of the pharmaceutical industry.
The budget included other steps friendly to generics makers. The administration said it wants to end “evergreening,” in which brand-name makers reformulate existing products and extend the life of their market exclusivity.
The proposals on generic drugs are part of a series of spending curbs that the president is proposing, all aimed at helping to reduce costs in the health care system overall and to pay for his effort to expand coverage to all Americans.
This is a small-bore initiative. But put enough small-bore initiatives together, and eventually you can have something pretty big.